Tc 99m apcitide

Drug Profile

Tc 99m apcitide

Alternative Names: AcuTect; P 280; Tc 99m P 280; Technetium Tc 99m apcitide; Technetium Tc 99m P280

Latest Information Update: 28 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals; Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals; Nihon Medi-Physics
  • Class Antithrombotics; Cyclic peptides; Organotechnetium compounds; Radiopharmaceuticals; Technetium compounds
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Deep vein thrombosis

Most Recent Events

  • 04 Apr 2007 Berlex Inc has been acquired by Bayer HealthCare
  • 29 Dec 2006 Schering AG is now called Bayer Schering Pharma AG
  • 19 Sep 2006 Discontinued - Preclinical for Deep vein thrombosis diagnosis in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top